Organon & Co. Common Stock vs Roblox Corp — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Roblox Corp trades at $46.91 (market cap $35.37B). The key difference: Roblox Corp is far larger — about 9.8× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Roblox Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Roblox Corp for 94 Days on average.
| OGN | RBLX | |
|---|---|---|
Market Cap | $3.62B | $35.37B |
Volume | 2,892,999 | 6,569,814 |
Sector | Health | Technology |
52-Week High | $13.81 | $138.56 |
52-Week Low | $5.70 | $35.54 |
Typical Hold Time | 0 Days | 94 Days |
Enterprise Value | $11.04B | $34.19B |
Dividend Yield | 0.58% | — |
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Roblox (RBLX) trades at $47.54, down 4.13% today amid mixed technical signals and analyst concerns about bookings growth. The stock shows strong revenue growth (2025: $4.89B, up 36% year-over-year) but remains unprofitable with a -17.61% net margin. Recent technical analysis indicates bullish moving averages but neutral oscillators, with key resistance at $50-$52. The company continues to beat earnings expectations, with Q2 2026 EPS of -$0.26 beating estimates by 24%.
Investment outlook balances strong user engagement and AI-driven creator tools against persistent profitability challenges. Analyst consensus sits at $51.35 with 42% buy ratings, though recent Jefferies downgrade to Underperform highlights concerns about valuation sustainability. Key risks include decelerating bookings growth and high P/B ratio of 232.69, while opportunities lie in AI-powered platform expansion and $3 billion buyback program.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →